Helicobacter pylori and Nonmalignant Diseases

• Published in: Helicobacter (Cambridge, Mass.) Mass.), 2015-09, Vol.20 (S1), p.26-29
• Main Authors: Potamitis, Georgios S., Axon, Anthony T. R.
• Format: Article
• Language: English
• Subjects: Anti-Bacterial Agents - therapeutic use; Disease; Drug Therapy, Combination; Dyspepsia - etiology; Dyspepsia - microbiology; Dyspepsia - pathology; functional dyspepsia; Gastroesophageal reflux; Gastroesophageal Reflux - etiology; Gastroesophageal Reflux - microbiology; Gastroesophageal Reflux - pathology; gastroesophageal reflux disease; Helicobacter Infections - drug therapy; Helicobacter Infections - microbiology; Helicobacter Infections - pathology; Helicobacter pylori; Helicobacter pylori - pathogenicity; Humans; Infections; nonsteroidal anti-inflammatory drugs; Peptic Ulcer - etiology; Peptic Ulcer - microbiology; Peptic Ulcer - pathology; Peptic ulcer disease; Proton Pump Inhibitors - therapeutic use; Ulcers
• ISSN: 1083-4389; 1523-5378
• DOI: 10.1111/hel.12253

Helicobacter pylori is responsible for most peptic ulcers, plays a role in functional dyspepsia and is thought by some to influence the course of gastroesophageal reflux disease. This article addresses recent studies that have been published in connection with these diseases. H. pylori‐associated peptic ulcer is declining in prevalence but the incidence of perforation and bleeding remains high especially in the elderly. All H. pylori associated peptic ulcers should be treated by eradication of the infection. Dyspepsia is a common disorder that affects up to 25% of the population. About 8% of cases that are infected with H. pylori will respond to treatment of the infection. The association between H. pylori and gastroesophageal reflux disease continues to be debated, a number of studies have shown that there is a negative association between H. pylori infection and Gastroesophageal reflux disease but treatment of H. pylori has not been shown to induce reflux or to affect the response to medication. Gastric atrophy is known to extend when acid suppression is used in infected patients implying that H. pylori treatment should be used in infected patients who are to undergo long‐term Proton Pump Inhibitor therapy.